Factory Supply High Purity 99% Liraglutide CAS No. 204656-20-2

Min.Order: 50
Product origin: Zhengzhou, Henan, China
Infringement complaint: complaintComplaint
US$ 50 ~ 80

Description
Product Description

Product Name: Liraglutide
Synonyms:Liraglutide Acetate,Liraglutidum,Liraglutidum Powder
Cas No.: 204656-20-2
Formula: C172h265n43o51

Formula Weight: 3751.202
Appearance:White lyophilized powder
After reconstitution store at 2°C - 8°C

    Powder
What is Liraglutide?
 

Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name as a treatment for obesity in adults with at least one weight-related comorbid condition.

Liraglutide was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.
 

Usage:
In common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.

Product Benefits:

  • Weight loss 
  • Anti-diabetes
  • Alzheimer's disease.
COA
AppearanceWhite powder.
Purity99%min
Single Impurity (HPLC) 1.0%max
Amino Acid Composition ±10% of theoretical
Peptide Content (N%) ≥80.0%
Water Content(Karl Fischer) ≤6.0%
Acetate Content (HPIC)≤15.0%
MS(ESI)Consistent
Mass Balance 95.0~105.0%
Specific Rotation (20/D) -65.0~-75.0°(c=0.5 1%HAc)
SolubilityH 2 O:40 mg / mL
Storage condition-20ºC
Shelf life2 years


Our main products: 
 Product Name Cas No.
Retatrutide2381089-83-2

Elamipretide

736992-21-5 
Liraglutide204656-20-2
semaglutide910463-68-2
Oxytocin50-56-6
Integrilin188627-80-7
Tirzepatide2023788-19-2
  
 
 



Product Tag:
Related categories:
Scroll to Top